Summary.-A panel of 5 different breast-cancer and 2 other cancer extracts was used to clarify the false-negative responses in patients with Stage I and II breast cancer and the false-positive responses in control subjects. Most patients with Stage I and II breast cancer who had an initially negative LAI response were positive when tested against the panel. The false negatives occurred because of (1) the experimental errors of the assay; (2) changes in the antigenic strength of the extracts; (3) antigenic heterogeneity of a few tumours and (4) lack of tumour-specific reactivity of the host. 3%0 of control subjects had a false-positive LAI response. The leucocytes from most of these positive patients did not react to the panel of antigens, and hence the false positives appeared to result from experimental error. In-hospital patients with benign breast disease had a 12% positivity rate when initially assayed, and 63% of these patients reacted to the panel of breast-cancer antigens. Those patients with benign breast disease who reacted to the panel of breast-cancer antigens had cytophilic anti -breast -cancer antibody in their serum; their leucocyte LAI reactivity was blocked in an immunologically specific manner by serum from advanced Stage IV breast-cancer patients; their leucocytes reacted to extracts of breast cancer and not fibrocystic breast tissue; their leucocyte reactivity was blocked by isolated breastcancer TSA that was linked to /2 microglobulin, but not by normal breast-tissue proteins; and the kinetics of the LAI response after excision of the breast mass was identical to that observed with breast-cancer patients after mastectomy. In these patients, the breast tissue within the breast lump expressed breast TSA similar to unequivocal breast cancer.
LEUCOCYTES from about 80°O of patients with Stage I and II breast cancer reacted in the tube LAI assay (Grosser & Thomson, 1975; Flores et al., 1977; Lopez et al., 1978) whereas leucocytes from less than 500 of control subjects reacted in the assay. Although the latter figure was considered to result from the variability of a biological assay, no systematic study of the false-positive patients had been undertaken to prove that the patients were not, in fact, sensitized to a breast-cancer antigen.
Conversely, there was no explanation why a minority of patients with Stage I and 11 breast cancer did not react in the tube LAI assay. In addition, patients with benign breast disease had a higher rate of LAI positivity (Lopez et al., 1978; Flores et al., 1977) than other control subjects, and this raised the possibility that some of these patients were reacting to breast-cancer antigens (Flores et al., 1977; Lopez et al., 1978) .
Because the tube LAI is a reliable assay, reproducible in vitro, for the detection of sensitization to tumourspecific antigens (Grosser & Thomson, 1975;  Marti Flores et al., 1977; Lopez et al., 1978; these observations were considered to be accurate, and the present study was undertaken to define, if possible, the reason for the false-positive and negative LAI responses. To investigate these, the leucocytes from the subject were reacted against a panel of extracts of breast cancer and unrelated tumour. The panel of antigens was used on the assumption that the leucocytes from a false-negative patient might show reactivity to other breast-cancer extracts if there was some heterogeneity of breast-cancer tumour antigens, or if the initial test antigen had lost its activity. On the other hand, the panel of antigens was used to test leucocytes from patients who had falsepositive reactions, on the assumption that if the leucocytes recognized a tumourspecific antigen, they should react to most other extracts of breast cancer. If the positive response to the initial test antigen resulted from some idiosyncrasy of the initial test extract, or from experimental error, an LAI response to different breast-cancer extracts would not be expected. The validity of this approach for clarifying the false-positive and negative LAI responses is shown in the results presented in this study.
MATERIALS AND METHODS
Sub jects.-The patients with false-positive and negative LAI responses were drawn from a total of 451 patients tested in the coded study of Lopez et al. (1978) .
Tumour extracts and tumour panels.-The preparation of the cancer extracts has been previously described in detail (Grosser & Thomson, 1975; Flores et al., 1977; Lopez et al., 1978; extracts was 100 ± 10 Hug per assay tube, since this amount was optimal (Grosser & Thomson, 1975; Flores et atl., 1977; Lopez et al., 1978; . Each sample of tumour extract for the panel was used once and then discarded; samples were stored at -40°C. Antigen-induced tube leucocyte-adherence inhibition (tube LAI) assay.-In a series of test tubes, 106 peripheral-blood leucocytes (PBL) were plated in the presence of extracts of specific breast cancer, control melanoma and Medium 199 as previously described (Grosser & Thomson, 1975; Flores et al., 1977; Lopez et al., 1978; . The tubes were incubated horizontally at 37°C in a 5% CO2 humidified atmosphere and after 2 h the number of nonadherent cells was counted in a haemocytometer and the nonadherence index (NAI) was calculated as previously described (Grosser & Thomson, 1975; & others) .
An NAI value > 30 was positive, < 30 was negative (Flores et al., 1977; Lopez et al., 1978; .
Arming of control leucocytes by serum from reactive patients.-PBL from control subjects were preincubated with serum from reactive breast-cancer patients, control subjects and from the patient with benign breast disease whose leucocytes showed LAI reactivitv.
After preincubation with the serum, the PBL were freed of excess serum by washing twice with 10 ml of Medium 199, and then plated in the standard antigen-induced tube LAI assay (AMarti et al., 1976) . The nonadherent cells were counted after 2 h incubation and the NAI calculated.
Blocking of LAI activiry by serum and papain-solutble antigens.-PBL from reactive breast-cancer patients (Stages I and II), from control subjects with negative LAI assays, and from patients with benign breast disease with a positive LAI assay, were preincubated with serum from either advanced nonreactive Stage IV breastcancer patients or cointrol subjects. After incubation for 30 min at 37°C in a 50 C03 atmosphere, the cells were washed with 10 inl of Medium 199 to remove excess serum, and the PBL were then plated in the standard tube LAI assay . Table 11 of the paper by Lopez et al. (1978) (Fazekas and MacFarlane, 1977; Fazekas et al., 1978) (kindly performed by Dr Fazekas, Dept. of Surgery) showed these to be high.
RESULTS
The other 3 patients (Nos. 12, 41, 18), when tested against the breast-cancerantigen panel, reacted to the other breast-cancer antigens but failed to react to the "Wolf" breast-cancer extract. The failure to react to the "Wolf" extract in Patient No. 12 was attributed to a partial loss of antigenic activity of that extract, since the patient subsequently reacted on 2 separate occasions to a fresh extract of the "Wolf" breast cancer. In the patients with unrelated cancer, 3/92 were positive in the initial assay and, when tested against the panel, 1 remained positive, whereas the other 2 were negative (Table IV) (Table IV) . LAI+ BBD patients PBL from the BBD patients who were positive against the panel were tested in the blocking tube LAI assay with serum from both patients with advanced breast cancer and normal subjects. The LAI activity of the reactive cells from BBD patients was blocked by serum from advanced breast-cancer patients but not from control subjects (Table V) . Moreover, the blocking was immunologically specific, since serum from nonreactive patients with Stage IV melanoma did not block the LAI activity. Similarlv, serum from LAI+ BBD patients was able to arm leucocytes from control subjects to react in the tube LAI assay in an immunologically specific manner against the breast-cancer extract (Table V) (Table V) .
To determine whether LAI+ and LAI-BBD patients showed any difference in the histological appearance of their fibrocystic disease, the histological sections from 10 LAI-and 5 LAI+ BBD patients were reviewed blindly by D.M. and were scored with respect to degree of atypia in the duct linings, according to the criteria described by Black et al. (1972) . The LAI-BBD patients were scored as 2 or less, whereas 2 of the 5 LAI+ BBD patients were scored as 3 to 4, and 2 were scored as 2. isolated from the tissues listed and the membrane proteins were solubilized by papain. The breast-cancer antigenic activity was then isolated by DEAE cellulose and Sephadex G-150 chromatography as previously described . Material from Sephadex G-150 Fraction 2 (70,000-150,000 mol. wt) was used in the blocking assay with 100 ,ug of protein added to the preincubation tubes in the presence of 5% FCS.
t Fraction 2 was then isolated by anti-human 92m affinity chromatography as previously described . In the blocking assay 200 [Lg of protein from the unbound and 50 tLg from the bound fraction were added to the preincubation tubes in the presence of 5% FCS.
$ When preincubated with LAI+ leucocytes from patients with colon cancer or malignant melanoma, the bound material did not abrogate their specific reactivity. patient reacts to the extract of breast cancer and not to the extract of breast tissue containing fibrocystic disease.
A more definitive and sensitive test of whether the LAI+ patient with BBD was reacting to a TSA of breast cancer and not a normal breast protein, was to perform blocking studies with papain-soluble membrane proteins from breast cancer, normal breast tissue and a melanoma control. Table VII shows that the LAI reactivity of the LAI+ BBD patient is blocked only by the isolated papain-soluble breastcancer-membrane tumour antigen. The reactivity of the breast-cancer patient is similarly blocked. Both patients tested with BBD who were LAI+ to the panel of breast antigen had their leucocyte reactivity blocked by the isolated papainsoluble breast-cancer TSA.
Kinetics of positive LAI in BBD patients
The patients with benign breast disease who were positive to the panel were monitored by tube LAI assay. With one exception, the LAI activity had disappeared within 2-4 months of the surgical biopsy. The one exception was a patient whose LAI reactivity disappeared at 7 months.
Lack of LAI reactivity of close family contactts
Laboratory personnel involved in handling breast-cancer tissue or blood from patients with breast-cancer, and family members living in the home of the patient with breast-cancer were assayed bv tube LAI. The 3 laboratory technicians with 3-years of frequent contact with breast-cancer extracts and blood products and members from 10 different families showed no LAI activity to extracts of breast cancer.
DISCUSSION
In a coded study, 17% and 28% of Stage I and II breast-cancer patients were initially LAI- (Lopez et al., 1978) . Theoretically, the leucocytes of these patients might, have been expected to display antitumour immunity. The present study showed that most of these initially LAIreacted to the panel of breast-cancer extracts. Thus most patients with localized breast cancer do exhibit systemic antitumour immunity.
There appear to be 4 major reasons for a negative LAI test in patients with localized (Stage I and II) breast cancer.
First, some had a negative LAI test as a result of experimental error of the assay. Second, deterioration in the antigenic activity of the extract can cause negative results. The loss of antigenic activity is often not an all-or-none phenomenon, and is therefore frequently recognized only in retrospect, when more patients than usual have negative assays. The PBS cancer extracts have a maximum "shelflife" of about 4-6 months when stored at -40°C, and when the extracts are used beyond 4 months more negative responses are frequently obtained. Third, the breastcancer extract used as the initial test antigen may not have the same antigen as the patient's own tumour. Antigenic heterogeneity, while it may exist in breast cancers, does not, however, appear to be a common problem. In contrast, antigenic heterogeneity in lhepatoma of' the liver appears to be common (Halliday et al., personal communication) . Fourth, leucocytes from some patients may not be responding immunologically to their cancer and will not respond in the assay.
The leucocytes from one patient with Stage I breast cancer, even when tested with multiple breast-tumour extracts including her own, showed no LAI activity. Lack of reactivity to the tumour was not due to failure of the tumour to express TSAs, since an extract of this tumour had specific antigen activity in the tube LAI assay against leucocytes from other reactive breast-cancer patients. The possibility that the patient had undetected widespread cancer and excess circulating TSA that abrogated LAI activity Lopez & Thomson, 1978) was not supported by blocking studies, since her serum failed to block LAIreactive leucocytes from patients with breast cancer. The tumour had high levels of cortisol receptors (Fazekas & MacFarlane, 1977) which concentrate cortisol within the tumour. We have previously reported that patients' NAI values and cortisol receptor concentration in the tumours were inversely correlated, and we speculated that high levels of cortisol within breast cancers may impair the afferent limb of the immune response (Fazekas et al., 1979) . Nevertheless, since the LAI activity of many patients with Stage III and IV breast cancer is abrogated by excess circulating TSA from the large tumour burden, some patients with Stage I and II cancer can be expected also to lack LAI reactivity because they have a more advanced stage of cancer than was detected clinically. In the present study, however, PBL from the one patient who definitely showed no LAI reactivity appeared not to react for another reason.
The other problem encountered in in vitro tube LAI assay was false-positive LAI responses. Three per cent of control subjects with either unrelated malignancies or nonmalignant diseases were LAI+. When these patients were tested against the panel of antigens, most were shown to be negative; i.e. the initial result was an experimental error. In the 2 patients who were positive to the panel, one had BBD and ovarian cancer, and the benign breast disease may have been the source of antigenic stimulation, since ovarian cancers have been used as tumour extracts without evidence of cross-reactivity with breast-cancer, and other patients with similar tumours have not reacted to breast-cancer extracts. The explanation for the male patient with a hernia who had a positive LAI response to the panel is unknown. He had no history of contact with breast-cancer patients. In this context, a number of investigators (Burger et al., 1977; G-raham-Pole et al., 1976; Byers et al., 1975; Morton & Malmgren, 1968) have reported that close family contacts of cancer patients may be sensitized to the cancer since they react in in vitro assays that measure antitumour immunity. Although extensive family studies were not undertaken, no positive responses were recorded in the 10 families tested. In addition, 3 members of the laboratory staff who have been extensively exposed to tumour extracts and products from breast-cancer patients had no positive LAI response to breastcancer extracts.
In-hospital patients with benign breast disease had a higher rate (12%) of positive responses in the tube LAI assay (Flores et al., 1977; Lopez et al., 1978) than control subjects. By contrast, a control group of patients with BBD tested randomly from the outpatient mammography clinic had a low rate (2%) of LAI+ responses (Lopez et al., 1978) . The in-hospital patients with BBD were admitted to hospital because in the opinion of the surgeon the breast mass, from the history and examination, was thought to be cancer rather than benign disease. Histological examination of the excised breast tissues from the in-hospital patients with BBD (both LAI+ and LAI-) revealed that some of the breast tissue from the positive responders had more marked hyperplasia of the epithelium and inflammatory infiltrates than that from the negative responders. In no instances, however, were there changes that the pathologist scored as carcinoma in situ (Grade 5).
Proof that extracts of the excised breast masses were able to act similarly to extracts of breast cancer in producing antigen-induced LAI is not available, because of ethical considerations. Nevertheless, the other evidence strongly suggests that breast lesions from LAI+ patients that were histopathologically benign expressed the TSA of breast cancer. The LAI+ BBD patients had cytophilic antitumour antibodies in their serum that were able to arm normal leucocytes to respond in an immunologically specific manner to extracts of breastcancer. The LAI+ leucocytes of the BBD patients were blocked in an immunologically specific manner by serum from advanced breast-cancer patients. The leucocytes showed LAI activity to extracts of breast cancer and not to extracts of fibrocystic disease from patients whose leucocytes had no LAI activity. The leucocytes from LAI+ patients with BBD were blocked by papain-soluble breastcancer TSA isolated from the membrane of breast-cancer cells Thomson et al., 1976) but the leucocytes were not blocked by proteins isolated in an identical manner from normal breast tissue or malignant melanoma. After excision of the breast mass, the kinetics of the antitumour immune response of the LAI+ patient with BBD were identical to those of breast-cancer patients after mastectomy (Flores et al., 1977; Lopez et al., 1978) . Moreover, the loss of LAI activity after excision of the breast mass suggests that the source of the antigenic stimulus was confined to the lesion removed and not present, at least in enough quantity to evoke an immune response, in the remaining breast tissue which still contained fibrocystic disease. In all 5 patients, the LAI response of the LAI+ patient with BBD was identical to that for breast-cancer patients. Hence, the lesions of the LAI+ patients with BBD appear to express a similar TSA to that of unequivocal breast cancer. Although in some of the patients there was epithelial hyperplasia and atypia, histologically these changes did not amount to carcinoma in situ.
The biological implications of these findings are intriguing. It would appear that the breast tissue has undergone a transformation typical of carcinoma, without any morphological sign of unequivocal malignancy. Whether this implies an early, irretrievable step on the way to invasive carcinoma, or whether this change is reversible and is an expression of unusual but controlled cell proliferation cannot be resolved.
Certainly, it is known that patients with "benign" mammary dysplasia have a higher incidence of breast-cancer (Monson et al., 1976; Haagensen, 1977; Donnelly et al., 1975) . Again, in the mouse angiogenesis, a property of carcinomas but not of resting mammary gland, appears earlier than any morphological evidence of malignancy in mouse papillomas which frequently progress toward invasive carcinoma (Brem et al., 1977) .
The present study showed that most patients with clinically detectable localized cancer (Stage I and II) manifested systemic antitumour immunity. Conversely, with the exception of a few patients of a select group of in-hospital patients with benign breast disease, most patients without breast cancer displayed no LAI activity to breast-cancer antigens and false-positive LAI responses were the result of experimental error, with an incidence of less than 5% against a single extract. By the use of a panel of breastcancer antigens including testing the patient against her own tumour, it was possible to clarify, in most instances, false LAI+ or LAI-responses. Unfortunately, the use of a panel of antigens is too tedious to be used for routine testing.
